Brief Research Communication

Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary report

  1. Ming T. Tsuang1,2,*,
  2. Nadine Nossova3,
  3. Tom Yager3,
  4. Min-Min Tsuang4,
  5. Shi-Chin Guo4,
  6. Kou Ge Shyu5,
  7. Stephen J. Glatt1,
  8. C.C. Liew3,*

Article first published online: 11 JAN 2005

DOI: 10.1002/ajmg.b.30161

Issue

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

Volume 133B, Issue 1, pages 1–5, 5 February 2005

Additional Information

How to Cite

Tsuang, M. T., Nossova, N., Yager, T., Tsuang, M.-M., Guo, S.-C., Shyu, K. G., Glatt, S. J. and Liew, C.C. (2005), Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: A preliminary report. Am. J. Med. Genet., 133B: 1–5. doi: 10.1002/ajmg.b.30161

Author Information

  1. 1

    Department of Psychiatry, Institute of Behavioral Genomics, University of California, San Diego, La Jolla, California

  2. 2

    Harvard Departments of Epidemiology and Psychiatry, Harvard Institute of Psychiatric Epidemiology and Genetics, Boston, Massachusetts

  3. 3

    ChondroGene, Inc., Toronto, Ontario, Canada

  4. 4

    Ju Shan Hospital, Taoyuan, Taiwan

  5. 5

    Shin Kong Medical Center, Taipei, Taiwan

*Department of Psychiatry, University Professor, University of California, Director, Institute of Behavioral Genomics, University of California, San Diego 9500 Gilman Drive, Mail Code 0603, Medical Teaching Facility, Room 453, La Jolla, CA 92093-0603.

Publication History

  1. Issue published online: 20 JAN 2005
  2. Article first published online: 11 JAN 2005
  3. Manuscript Accepted: 25 OCT 2004
  4. Manuscript Received: 10 SEP 2004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (191K)

Keywords:

  • blood biomarker;
  • differential diagnosis;
  • gene expression;
  • microarray;
  • schizophrenia;
  • bipolar disorder;
  • real-time RT-PCR;
  • logistic regression analysis;
  • ROC curve

Abstract

Recent advances have facilitated the use of blood-derived RNA to conduct genomic analyses of human diseases. This emerging technology represents a rigorous and convenient alternative to traditional tissue biopsy-derived RNA, as it allows for larger sample sizes, better standardization of technical procedures, and the ability to non-invasively profile human subjects. In the present pilot study, we have collected RNA from blood of patients diagnosed with schizophrenia or bipolar disorder (BPD), as well as normal control subjects. Using microarray analysis, we found that each disease state exhibited a unique expressed genome signature, allowing us to discriminate between the schizophrenia, BPD, and control groups. In addition, we validated changes in several potential biomarker genes for schizophrenia and BPD by RT-PCR, and some of these were found to code to chromosomal loci previously linked to schizophrenia. Linear and non-linear combinations of eight putative biomarker genes (APOBEC3B, ADSS, ATM, CLC, CTBP1, DATF1, CXCL1, and S100A9) were able to discriminate between schizophrenia, BPD, and control samples, with an overall accuracy of 95%–97% as indicated by receiver operating characteristic (ROC) curve analysis. We therefore propose that blood cell-derived RNA may have significant value for performing diagnostic functions and identifying disease biomarkers in schizophrenia and BPD. © 2005 Wiley-Liss, Inc.

View Full Article (HTML) Get PDF (191K)